Active, not recruitingPhase 3NCT04368559
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
Studying Invasive candidiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mundipharma Research Limited
- Principal Investigator
- Laura Cox, PhDMundipharma Research Limited
- Intervention
- Rezafungin for Injection(drug)
- Enrollment
- 602 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- UCLA Center for Health Sciences, Los Angeles, California, United States
- Stanford University School of Medicine, Stanford, California, United States
- Augusta University Medical Center, Augusta, Georgia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- University of Maryland Medical Center, Baltimore, Maryland, United States
- John Hopkins, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Minnesota Physicians, Minneapolis, Minnesota, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Mary Hitchcock Memorial Hospital Dartmouth-Hitchcock, Lebanon, New Hampshire, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Stony Brook University Hospital, Stony Brook, New York, United States
- The University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04368559 on ClinicalTrials.govOther trials for Invasive candidiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05421858A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.Basilea Pharmaceutica
- RECRUITINGPHASE2NCT06194201A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive CandidiasisFujian Shengdi Pharmaceutical Co., Ltd.
- RECRUITINGNCT06456151Invasive Candidiasis in Critical CareUniversity Hospital Ostrava
- RECRUITINGNANCT05763251Comparison of Uncomplicated Candidemia Therapy Duration in ChildrenArkansas Children's Hospital Research Institute
- RECRUITINGNANCT03538912Early Discontinuation of Empirical Antifungal Therapy and BiomarkersUniversity Hospital, Lille